bt 474 cells  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    ATCC bt 474 cells
    The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts reduced patient survival . ( A ) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor in the patient cohort , organized by ERBB2 status. ( B ) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both WT and KR receptors) in <t>BT-474</t> human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2 phosphorylation. ( C ) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated ER-positive tumors from the Loi et al. dataset . ( D ) Survival curves as in part C for patients whose tumors expressed the combined T47D metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files and ]. ER, estrogen receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.
    Bt 474 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 cells/product/ATCC
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 cells - by Bioz Stars, 2023-02
    97/100 stars

    Images

    1) Product Images from "Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression"

    Article Title: Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression

    Journal: Breast Cancer Research : BCR

    doi: 10.1186/bcr3211

    The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts reduced patient survival . ( A ) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor in the patient cohort , organized by ERBB2 status. ( B ) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both WT and KR receptors) in BT-474 human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2 phosphorylation. ( C ) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated ER-positive tumors from the Loi et al. dataset . ( D ) Survival curves as in part C for patients whose tumors expressed the combined T47D metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files and ]. ER, estrogen receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.
    Figure Legend Snippet: The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts reduced patient survival . ( A ) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor in the patient cohort , organized by ERBB2 status. ( B ) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both WT and KR receptors) in BT-474 human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2 phosphorylation. ( C ) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated ER-positive tumors from the Loi et al. dataset . ( D ) Survival curves as in part C for patients whose tumors expressed the combined T47D metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files and ]. ER, estrogen receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.

    Techniques Used: Expressing, Quantitative RT-PCR, Western Blot, Mutagenesis

    bt 474  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC bt 474
    MCF-7, <t>BT-474,</t> and EFM-192a cells were stimulated with 50ng/mL of either FGF2 or FGF4 supplemented with 5µg/mL of heparin. After 0, 30, and 60 minutes, the cells were harvested and subjected to measurement using the targeted kinome assay. The heatmap shows the quantified activation-determining phosphorylated sites on the kinases (biological triplicates). Only significantly changing values are shown (ANOVA p < 0.05).
    Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 - by Bioz Stars, 2023-02
    86/100 stars

    Images

    1) Product Images from "Elucidating Fibroblast Growth Factor-induced kinome dynamics using targeted mass spectrometry and dynamic modeling"

    Article Title: Elucidating Fibroblast Growth Factor-induced kinome dynamics using targeted mass spectrometry and dynamic modeling

    Journal: bioRxiv

    doi: 10.1101/2023.01.27.525819

    MCF-7, BT-474, and EFM-192a cells were stimulated with 50ng/mL of either FGF2 or FGF4 supplemented with 5µg/mL of heparin. After 0, 30, and 60 minutes, the cells were harvested and subjected to measurement using the targeted kinome assay. The heatmap shows the quantified activation-determining phosphorylated sites on the kinases (biological triplicates). Only significantly changing values are shown (ANOVA p < 0.05).
    Figure Legend Snippet: MCF-7, BT-474, and EFM-192a cells were stimulated with 50ng/mL of either FGF2 or FGF4 supplemented with 5µg/mL of heparin. After 0, 30, and 60 minutes, the cells were harvested and subjected to measurement using the targeted kinome assay. The heatmap shows the quantified activation-determining phosphorylated sites on the kinases (biological triplicates). Only significantly changing values are shown (ANOVA p < 0.05).

    Techniques Used: Activation Assay

    FGFR expression levels were quantified using qPCR in MCF-7, BT-474, and EFM-192a cells using FGFR subtype-specific primers (triplicate measurements) ( Supplementary table 5 ). Beta-actin and Glyceraldehyde-3-phosphate dehydrogenase was quantified to enable normalization across cell types. Reported values are the quantitation cycles (Cq) that negatively correlates with the RNA expression levels.
    Figure Legend Snippet: FGFR expression levels were quantified using qPCR in MCF-7, BT-474, and EFM-192a cells using FGFR subtype-specific primers (triplicate measurements) ( Supplementary table 5 ). Beta-actin and Glyceraldehyde-3-phosphate dehydrogenase was quantified to enable normalization across cell types. Reported values are the quantitation cycles (Cq) that negatively correlates with the RNA expression levels.

    Techniques Used: Expressing, Quantitation Assay, RNA Expression

    bt 474  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC bt 474
    Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 - by Bioz Stars, 2023-02
    86/100 stars

    Images

    bt 474 cell line  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC bt 474 cell line
    The targeting ability of the NIHA complex. The CLSM images of <t>BT-474</t> cells incubated with the NIHA complex (up) and the nanobubble-Dil-HPPH complex (down). Bar, 50 μm.
    Bt 474 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 cell line/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 cell line - by Bioz Stars, 2023-02
    86/100 stars

    Images

    1) Product Images from "The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer"

    Article Title: The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer

    Journal: International Journal of Nanomedicine

    doi: 10.2147/IJN.S387409

    The targeting ability of the NIHA complex. The CLSM images of BT-474 cells incubated with the NIHA complex (up) and the nanobubble-Dil-HPPH complex (down). Bar, 50 μm.
    Figure Legend Snippet: The targeting ability of the NIHA complex. The CLSM images of BT-474 cells incubated with the NIHA complex (up) and the nanobubble-Dil-HPPH complex (down). Bar, 50 μm.

    Techniques Used: Incubation

    ( A ) Cell viability of BT-474 cells detected via CCK-8. ( B ) The apoptotic ratio of BT-474 cells detected via Annexin-V flow cytometry. ** P < 0.01 compared with the NIHA-laser group.
    Figure Legend Snippet: ( A ) Cell viability of BT-474 cells detected via CCK-8. ( B ) The apoptotic ratio of BT-474 cells detected via Annexin-V flow cytometry. ** P < 0.01 compared with the NIHA-laser group.

    Techniques Used: CCK-8 Assay, Flow Cytometry

    CLSM images of BT-474 cells in the NIHA-laser, NIHA, laser, and the control groups. The nuclei of the apoptosis cells were stained by using PI (depicted as red fluorescence). Bar, 30 μm.
    Figure Legend Snippet: CLSM images of BT-474 cells in the NIHA-laser, NIHA, laser, and the control groups. The nuclei of the apoptosis cells were stained by using PI (depicted as red fluorescence). Bar, 30 μm.

    Techniques Used: Staining, Fluorescence

    bt 474 cells cat htb 20 cells  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC bt 474 cells cat htb 20 cells
    MCF-7 and <t>BT-474</t> cells were cultured on soft (0.5 kPa) or stiff (9 kPa) supports for 2 weeks before subsequent analysis. a Docetaxel (Doc) induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. The proportions of Annexin V + cells are shown. b Quantitation of apoptotic cells (Annexin V + ) in MCF-7 and BT-474 cells in (a) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. c MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated after 24 h by CCK8 assays ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. d Western blots for cleaved/uncleaved caspase-3 and PARP in docetaxel-treated MCF-7 and BT-474 cells cultured on soft or stiff supports. Representative images from 3 biologically independent experiments are shown. e The percentage of CD44 high CD24 low cells in MCF-7 and BT-474 cells cultured on soft or stiff supports were determined by flow cytometry. f Quantitation of CD44 high CD24 low cells in (e) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. For b-d and f , source data are provided as a Source Data file.
    Bt 474 Cells Cat Htb 20 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 cells cat htb 20 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 cells cat htb 20 cells - by Bioz Stars, 2023-02
    86/100 stars

    Images

    1) Product Images from "Niche stiffness sustains cancer stemness via TAZ and NANOG phase separation"

    Article Title: Niche stiffness sustains cancer stemness via TAZ and NANOG phase separation

    Journal: Nature Communications

    doi: 10.1038/s41467-023-35856-y

    MCF-7 and BT-474 cells were cultured on soft (0.5 kPa) or stiff (9 kPa) supports for 2 weeks before subsequent analysis. a Docetaxel (Doc) induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. The proportions of Annexin V + cells are shown. b Quantitation of apoptotic cells (Annexin V + ) in MCF-7 and BT-474 cells in (a) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. c MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated after 24 h by CCK8 assays ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. d Western blots for cleaved/uncleaved caspase-3 and PARP in docetaxel-treated MCF-7 and BT-474 cells cultured on soft or stiff supports. Representative images from 3 biologically independent experiments are shown. e The percentage of CD44 high CD24 low cells in MCF-7 and BT-474 cells cultured on soft or stiff supports were determined by flow cytometry. f Quantitation of CD44 high CD24 low cells in (e) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. For b-d and f , source data are provided as a Source Data file.
    Figure Legend Snippet: MCF-7 and BT-474 cells were cultured on soft (0.5 kPa) or stiff (9 kPa) supports for 2 weeks before subsequent analysis. a Docetaxel (Doc) induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. The proportions of Annexin V + cells are shown. b Quantitation of apoptotic cells (Annexin V + ) in MCF-7 and BT-474 cells in (a) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. c MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated after 24 h by CCK8 assays ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. d Western blots for cleaved/uncleaved caspase-3 and PARP in docetaxel-treated MCF-7 and BT-474 cells cultured on soft or stiff supports. Representative images from 3 biologically independent experiments are shown. e The percentage of CD44 high CD24 low cells in MCF-7 and BT-474 cells cultured on soft or stiff supports were determined by flow cytometry. f Quantitation of CD44 high CD24 low cells in (e) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. For b-d and f , source data are provided as a Source Data file.

    Techniques Used: Cell Culture, Flow Cytometry, Quantitation Assay, Western Blot

    MCF-7 and BT-474 cells were cultured on soft or stiff supports for 2 weeks before subsequent analysis. In some experiments, cells were pre-transduced with TAZ shRNA (shTAZ-1 or shTAZ-2) or GFP shRNA (shGFP). a The expression of TAZ in MCF-7 and BT-474 cells cultured on soft or stiff supports was determined by western blot ( n = 3 biologically independent experiments). b Representative immunofluorescence staining of TAZ in MCF-7 and BT-474 cells cultured on soft or stiff substrates. The insert represents a magnification from the indicated area (white square). Scale bars, 10 μm. c Proportion of cancer cells exhibiting mainly nuclear TAZ localization (N > C), diffuse distribution of TAZ in nucleus and cytoplasm (N = C), or preferential cytoplasmic TAZ (N < C or undetectable). 20 cells were assessed per group, experiments were independently repeated 4 times. Mean ± SD, **** p < 0.0001 by two-tailed chi-square test. d Docetaxel induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. See Supplementary Fig. for quantification. e MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated by CCK8 assay ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided one-way ANOVA with Tukey test. f Representative images of CD44 high CD24 low cells in MCF-7 and BT-474 cells were detected by flow cytometry. See Supplementary Fig. for quantification. g Western blots of TAZ, SOX2, and OCT4 in MCF-7 and BT-474 cells cultured on soft or stiff supports ( n = 3 biologically independent experiments). For data presented in the same figure panel, the samples were derived from the same experiment and blots were processed in parallel. For a , c , e and g , source data are provided as a Source Data file.
    Figure Legend Snippet: MCF-7 and BT-474 cells were cultured on soft or stiff supports for 2 weeks before subsequent analysis. In some experiments, cells were pre-transduced with TAZ shRNA (shTAZ-1 or shTAZ-2) or GFP shRNA (shGFP). a The expression of TAZ in MCF-7 and BT-474 cells cultured on soft or stiff supports was determined by western blot ( n = 3 biologically independent experiments). b Representative immunofluorescence staining of TAZ in MCF-7 and BT-474 cells cultured on soft or stiff substrates. The insert represents a magnification from the indicated area (white square). Scale bars, 10 μm. c Proportion of cancer cells exhibiting mainly nuclear TAZ localization (N > C), diffuse distribution of TAZ in nucleus and cytoplasm (N = C), or preferential cytoplasmic TAZ (N < C or undetectable). 20 cells were assessed per group, experiments were independently repeated 4 times. Mean ± SD, **** p < 0.0001 by two-tailed chi-square test. d Docetaxel induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. See Supplementary Fig. for quantification. e MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated by CCK8 assay ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided one-way ANOVA with Tukey test. f Representative images of CD44 high CD24 low cells in MCF-7 and BT-474 cells were detected by flow cytometry. See Supplementary Fig. for quantification. g Western blots of TAZ, SOX2, and OCT4 in MCF-7 and BT-474 cells cultured on soft or stiff supports ( n = 3 biologically independent experiments). For data presented in the same figure panel, the samples were derived from the same experiment and blots were processed in parallel. For a , c , e and g , source data are provided as a Source Data file.

    Techniques Used: Cell Culture, Transduction, shRNA, Expressing, Western Blot, Immunofluorescence, Staining, Two Tailed Test, Flow Cytometry, CCK-8 Assay, Derivative Assay

    a – d TAZ and NANOG were knockout or overexpressed by lentiviral transfection in MCF-7 and BT-474 cells. NANOG, TAZ, SOX2 or/and OCT4 were overexpressed in TAZ or NANOG knockout cells. Transfected cells were cultured on stiff hydrogels for 2 weeks. OE, overexpression. a (Left) Representative flow cytometric plot indicating the percentages of CD44 high CD24 low cells in MCF-7 and BT-474 cells. (Right) Qualification of five biologically independent experiments. **** p < 0.0001; for MCF-7 cells, *** p = 0.0003, ** p = 0.0039, ns=0.9899; for BT-474 cells, *** p = 0.0008, ns=0.9982. b Cell viability of MCF-7 and BT-474 cells treated with various concentrations of docetaxel and cisplatin for 24 h was determined by CCK8 assays ( n = 4 biologically independent experiments). P values compared with sgTAZ + Vector group were shown in the figure. c (Left) Representative flow cytometric plot indicating the percentages of CD44 high CD24 low cells in MCF-7 and BT-474 cells. (Right) Qualification of five independent experiments. **** p < 0.0001; for MCF-7 cells, *** p = 0.0004, ** p = 0.0033, ns=0.9400; for BT-474 cells, *** p = 0.0002, ** p = 0.0013, ns=0.9982. d Cell viability of MCF-7 and BT-474 cells treated with various concentrations of docetaxel and cisplatin for 24 h was determined by CCK8 assays ( n = 4 biologically independent experiments). P values compared with sgNANOG + Vector group were shown in the figure. For panels (a– d) , data are mean ± SD; p values were calculated by two-sided one-way ANOVA with Tukey test. e , f MCF-7 cells were cultured on soft or stiff hydrogels for 2 weeks. Then ChIP was performed using cell lysates with indicated antibodies. e The precipitated DNA using IgG and TAZ antibody, respectively, was quantified by qPCR with primers specific to promoter regions of Sox2 and Pou5f1 . f The precipitated DNA using IgG and NANOG antibody, respectively, was quantified by qPCR with primers specific to promoter regions of Sox2 and Pou5f1 . e , f Fold enrichment was normalized to IgG-ChIP negative control ( n = 4 biologically independent experiments). Numeric values denote mean ± SD; **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. For a–f , source data are provided as a Source Data file.
    Figure Legend Snippet: a – d TAZ and NANOG were knockout or overexpressed by lentiviral transfection in MCF-7 and BT-474 cells. NANOG, TAZ, SOX2 or/and OCT4 were overexpressed in TAZ or NANOG knockout cells. Transfected cells were cultured on stiff hydrogels for 2 weeks. OE, overexpression. a (Left) Representative flow cytometric plot indicating the percentages of CD44 high CD24 low cells in MCF-7 and BT-474 cells. (Right) Qualification of five biologically independent experiments. **** p < 0.0001; for MCF-7 cells, *** p = 0.0003, ** p = 0.0039, ns=0.9899; for BT-474 cells, *** p = 0.0008, ns=0.9982. b Cell viability of MCF-7 and BT-474 cells treated with various concentrations of docetaxel and cisplatin for 24 h was determined by CCK8 assays ( n = 4 biologically independent experiments). P values compared with sgTAZ + Vector group were shown in the figure. c (Left) Representative flow cytometric plot indicating the percentages of CD44 high CD24 low cells in MCF-7 and BT-474 cells. (Right) Qualification of five independent experiments. **** p < 0.0001; for MCF-7 cells, *** p = 0.0004, ** p = 0.0033, ns=0.9400; for BT-474 cells, *** p = 0.0002, ** p = 0.0013, ns=0.9982. d Cell viability of MCF-7 and BT-474 cells treated with various concentrations of docetaxel and cisplatin for 24 h was determined by CCK8 assays ( n = 4 biologically independent experiments). P values compared with sgNANOG + Vector group were shown in the figure. For panels (a– d) , data are mean ± SD; p values were calculated by two-sided one-way ANOVA with Tukey test. e , f MCF-7 cells were cultured on soft or stiff hydrogels for 2 weeks. Then ChIP was performed using cell lysates with indicated antibodies. e The precipitated DNA using IgG and TAZ antibody, respectively, was quantified by qPCR with primers specific to promoter regions of Sox2 and Pou5f1 . f The precipitated DNA using IgG and NANOG antibody, respectively, was quantified by qPCR with primers specific to promoter regions of Sox2 and Pou5f1 . e , f Fold enrichment was normalized to IgG-ChIP negative control ( n = 4 biologically independent experiments). Numeric values denote mean ± SD; **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. For a–f , source data are provided as a Source Data file.

    Techniques Used: Knock-Out, Transfection, Cell Culture, Over Expression, Plasmid Preparation, Negative Control

    bt 474  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC bt 474
    Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 - by Bioz Stars, 2023-02
    86/100 stars

    Images

    bt 474 breast cancer cells  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC bt 474 breast cancer cells
    Hierarchical clustering of RNA expression profiles. Panel A clustering analysis of expression profiles of 8 MCF-7 sublines along with those of 19 breast cancer cell lines. Expression profiling was done using home made Nylon arrays comprising 721 cDNAs corresponding to identified genes localized on either chromosome 1q or 17q. Panel B clustering analysis of profiles of 7 MCF-7 sublines and the <t>BT-474</t> breast cancer cell line. Nylon arrays comprised 1034 genes selected on the basis of their involvement in cancer. Clustering analysis wass done on raw quantification results, which were just subjected to a scaling step but not to ratio calculation. Parameters used in the analysis were Hierarchically Cluster Axes for Genesand Array: clusterand similarity metric correlation centered with average linkage clustering. The dendogram on top of the diagram represents cell lines ordered according to their degree of similarity. Complete datasets can be found at
    Bt 474 Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 breast cancer cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 breast cancer cells - by Bioz Stars, 2023-02
    86/100 stars

    Images

    1) Product Images from "Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications"

    Article Title: Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications

    Journal: BMC Cancer

    doi: 10.1186/1471-2407-3-13

    Hierarchical clustering of RNA expression profiles. Panel A clustering analysis of expression profiles of 8 MCF-7 sublines along with those of 19 breast cancer cell lines. Expression profiling was done using home made Nylon arrays comprising 721 cDNAs corresponding to identified genes localized on either chromosome 1q or 17q. Panel B clustering analysis of profiles of 7 MCF-7 sublines and the BT-474 breast cancer cell line. Nylon arrays comprised 1034 genes selected on the basis of their involvement in cancer. Clustering analysis wass done on raw quantification results, which were just subjected to a scaling step but not to ratio calculation. Parameters used in the analysis were Hierarchically Cluster Axes for Genesand Array: clusterand similarity metric correlation centered with average linkage clustering. The dendogram on top of the diagram represents cell lines ordered according to their degree of similarity. Complete datasets can be found at
    Figure Legend Snippet: Hierarchical clustering of RNA expression profiles. Panel A clustering analysis of expression profiles of 8 MCF-7 sublines along with those of 19 breast cancer cell lines. Expression profiling was done using home made Nylon arrays comprising 721 cDNAs corresponding to identified genes localized on either chromosome 1q or 17q. Panel B clustering analysis of profiles of 7 MCF-7 sublines and the BT-474 breast cancer cell line. Nylon arrays comprised 1034 genes selected on the basis of their involvement in cancer. Clustering analysis wass done on raw quantification results, which were just subjected to a scaling step but not to ratio calculation. Parameters used in the analysis were Hierarchically Cluster Axes for Genesand Array: clusterand similarity metric correlation centered with average linkage clustering. The dendogram on top of the diagram represents cell lines ordered according to their degree of similarity. Complete datasets can be found at

    Techniques Used: RNA Expression, Expressing

    bt 474 cells  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    ATCC bt 474 cells
    The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts reduced patient survival . ( A ) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor in the patient cohort , organized by ERBB2 status. ( B ) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both WT and KR receptors) in <t>BT-474</t> human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2 phosphorylation. ( C ) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated ER-positive tumors from the Loi et al. dataset . ( D ) Survival curves as in part C for patients whose tumors expressed the combined T47D metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files and ]. ER, estrogen receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.
    Bt 474 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 cells/product/ATCC
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 cells - by Bioz Stars, 2023-02
    97/100 stars

    Images

    1) Product Images from "Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression"

    Article Title: Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression

    Journal: Breast Cancer Research : BCR

    doi: 10.1186/bcr3211

    The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts reduced patient survival . ( A ) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor in the patient cohort , organized by ERBB2 status. ( B ) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both WT and KR receptors) in BT-474 human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2 phosphorylation. ( C ) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated ER-positive tumors from the Loi et al. dataset . ( D ) Survival curves as in part C for patients whose tumors expressed the combined T47D metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files and ]. ER, estrogen receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.
    Figure Legend Snippet: The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts reduced patient survival . ( A ) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor in the patient cohort , organized by ERBB2 status. ( B ) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both WT and KR receptors) in BT-474 human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2 phosphorylation. ( C ) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated ER-positive tumors from the Loi et al. dataset . ( D ) Survival curves as in part C for patients whose tumors expressed the combined T47D metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files and ]. ER, estrogen receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.

    Techniques Used: Expressing, Quantitative RT-PCR, Western Blot, Mutagenesis

    human breast carcinoma cell lines  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    ATCC human breast carcinoma cell lines
    Human Breast Carcinoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast carcinoma cell lines/product/ATCC
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human breast carcinoma cell lines - by Bioz Stars, 2023-02
    95/100 stars

    Images

    bt 474  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97

    Structured Review

    ATCC bt 474
    Tropomyosin 1 gene RNA isoform expression in breast cancer cell lines.
    Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474/product/ATCC
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 - by Bioz Stars, 2023-02
    97/100 stars

    Images

    1) Product Images from "Expression of Tropomyosin 1 Gene Isoforms in Human Breast Cancer Cell Lines"

    Article Title: Expression of Tropomyosin 1 Gene Isoforms in Human Breast Cancer Cell Lines

    Journal: International Journal of Breast Cancer

    doi: 10.1155/2015/859427

    Tropomyosin 1 gene RNA isoform expression in breast cancer cell lines.
    Figure Legend Snippet: Tropomyosin 1 gene RNA isoform expression in breast cancer cell lines.

    Techniques Used: Expressing

    Tropomyosin 1 RNA isoform frequencies in various human cardiac tissues and breast epithelial cell lines.
    Figure Legend Snippet: Tropomyosin 1 RNA isoform frequencies in various human cardiac tissues and breast epithelial cell lines.

    Techniques Used: Clone Assay

    Tropomyosin 1 protein expression in breast cancer cell lines.
    Figure Legend Snippet: Tropomyosin 1 protein expression in breast cancer cell lines.

    Techniques Used: Expressing

    Western blot analyses for tropomyosin protein expressed in various breast epithelial cell lines. Top panel is the western blot stained with Ponceau dye. Middle panel is the blot stained with anti-tropomyosin antibody TM311 that reacts with all tropomyosins containing exon 1a. Bottom panel is the western blot stained with anti-tropomyosin antibody CH1 that reacts with all tropomyosins containing exon 9a. Lane M, molecular weight marker; lane 1, MDAMB453; lane 2, HCC1419; lane 3, HCC1806; lane 4, MDAMB157; lane 5, BT474; lane 6, HCC1187; lane 7, HCC1143; lane 8, MDAMB468; lane 9, MCF7; lane 10, MCF10A; lane 11, HCC1143BL; lane 12 HCC1187BL; lane 13, skeletal muscle.
    Figure Legend Snippet: Western blot analyses for tropomyosin protein expressed in various breast epithelial cell lines. Top panel is the western blot stained with Ponceau dye. Middle panel is the blot stained with anti-tropomyosin antibody TM311 that reacts with all tropomyosins containing exon 1a. Bottom panel is the western blot stained with anti-tropomyosin antibody CH1 that reacts with all tropomyosins containing exon 9a. Lane M, molecular weight marker; lane 1, MDAMB453; lane 2, HCC1419; lane 3, HCC1806; lane 4, MDAMB157; lane 5, BT474; lane 6, HCC1187; lane 7, HCC1143; lane 8, MDAMB468; lane 9, MCF7; lane 10, MCF10A; lane 11, HCC1143BL; lane 12 HCC1187BL; lane 13, skeletal muscle.

    Techniques Used: Western Blot, Staining, Molecular Weight, Marker

    bt 474 egfr positive  (ATCC)


    Bioz Verified Symbol ATCC is a verified supplier
    Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 86

    Structured Review

    ATCC bt 474 egfr positive
    Bt 474 Egfr Positive, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 egfr positive/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 egfr positive - by Bioz Stars, 2023-02
    86/100 stars

    Images

    Similar Products

  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 97
    ATCC bt 474 cells
    The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts reduced patient survival . ( A ) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor in the patient cohort , organized by ERBB2 status. ( B ) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both WT and KR receptors) in <t>BT-474</t> human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2 phosphorylation. ( C ) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated ER-positive tumors from the Loi et al. dataset . ( D ) Survival curves as in part C for patients whose tumors expressed the combined T47D metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files and ]. ER, estrogen receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.
    Bt 474 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 cells/product/ATCC
    Average 97 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 cells - by Bioz Stars, 2023-02
    97/100 stars
      Buy from Supplier

    bt 474  (ATCC)
    86
    ATCC bt 474
    MCF-7, <t>BT-474,</t> and EFM-192a cells were stimulated with 50ng/mL of either FGF2 or FGF4 supplemented with 5µg/mL of heparin. After 0, 30, and 60 minutes, the cells were harvested and subjected to measurement using the targeted kinome assay. The heatmap shows the quantified activation-determining phosphorylated sites on the kinases (biological triplicates). Only significantly changing values are shown (ANOVA p < 0.05).
    Bt 474, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    86
    ATCC bt 474 cell line
    The targeting ability of the NIHA complex. The CLSM images of <t>BT-474</t> cells incubated with the NIHA complex (up) and the nanobubble-Dil-HPPH complex (down). Bar, 50 μm.
    Bt 474 Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 cell line/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 cell line - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    86
    ATCC bt 474 cells cat htb 20 cells
    MCF-7 and <t>BT-474</t> cells were cultured on soft (0.5 kPa) or stiff (9 kPa) supports for 2 weeks before subsequent analysis. a Docetaxel (Doc) induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. The proportions of Annexin V + cells are shown. b Quantitation of apoptotic cells (Annexin V + ) in MCF-7 and BT-474 cells in (a) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. c MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated after 24 h by CCK8 assays ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. d Western blots for cleaved/uncleaved caspase-3 and PARP in docetaxel-treated MCF-7 and BT-474 cells cultured on soft or stiff supports. Representative images from 3 biologically independent experiments are shown. e The percentage of CD44 high CD24 low cells in MCF-7 and BT-474 cells cultured on soft or stiff supports were determined by flow cytometry. f Quantitation of CD44 high CD24 low cells in (e) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. For b-d and f , source data are provided as a Source Data file.
    Bt 474 Cells Cat Htb 20 Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 cells cat htb 20 cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 cells cat htb 20 cells - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    86
    ATCC bt 474 breast cancer cells
    Hierarchical clustering of RNA expression profiles. Panel A clustering analysis of expression profiles of 8 MCF-7 sublines along with those of 19 breast cancer cell lines. Expression profiling was done using home made Nylon arrays comprising 721 cDNAs corresponding to identified genes localized on either chromosome 1q or 17q. Panel B clustering analysis of profiles of 7 MCF-7 sublines and the <t>BT-474</t> breast cancer cell line. Nylon arrays comprised 1034 genes selected on the basis of their involvement in cancer. Clustering analysis wass done on raw quantification results, which were just subjected to a scaling step but not to ratio calculation. Parameters used in the analysis were Hierarchically Cluster Axes for Genesand Array: clusterand similarity metric correlation centered with average linkage clustering. The dendogram on top of the diagram represents cell lines ordered according to their degree of similarity. Complete datasets can be found at
    Bt 474 Breast Cancer Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 breast cancer cells/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 breast cancer cells - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    95
    ATCC human breast carcinoma cell lines
    Hierarchical clustering of RNA expression profiles. Panel A clustering analysis of expression profiles of 8 MCF-7 sublines along with those of 19 breast cancer cell lines. Expression profiling was done using home made Nylon arrays comprising 721 cDNAs corresponding to identified genes localized on either chromosome 1q or 17q. Panel B clustering analysis of profiles of 7 MCF-7 sublines and the <t>BT-474</t> breast cancer cell line. Nylon arrays comprised 1034 genes selected on the basis of their involvement in cancer. Clustering analysis wass done on raw quantification results, which were just subjected to a scaling step but not to ratio calculation. Parameters used in the analysis were Hierarchically Cluster Axes for Genesand Array: clusterand similarity metric correlation centered with average linkage clustering. The dendogram on top of the diagram represents cell lines ordered according to their degree of similarity. Complete datasets can be found at
    Human Breast Carcinoma Cell Lines, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human breast carcinoma cell lines/product/ATCC
    Average 95 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    human breast carcinoma cell lines - by Bioz Stars, 2023-02
    95/100 stars
      Buy from Supplier

    86
    ATCC bt 474 egfr positive
    Hierarchical clustering of RNA expression profiles. Panel A clustering analysis of expression profiles of 8 MCF-7 sublines along with those of 19 breast cancer cell lines. Expression profiling was done using home made Nylon arrays comprising 721 cDNAs corresponding to identified genes localized on either chromosome 1q or 17q. Panel B clustering analysis of profiles of 7 MCF-7 sublines and the <t>BT-474</t> breast cancer cell line. Nylon arrays comprised 1034 genes selected on the basis of their involvement in cancer. Clustering analysis wass done on raw quantification results, which were just subjected to a scaling step but not to ratio calculation. Parameters used in the analysis were Hierarchically Cluster Axes for Genesand Array: clusterand similarity metric correlation centered with average linkage clustering. The dendogram on top of the diagram represents cell lines ordered according to their degree of similarity. Complete datasets can be found at
    Bt 474 Egfr Positive, supplied by ATCC, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/bt 474 egfr positive/product/ATCC
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    bt 474 egfr positive - by Bioz Stars, 2023-02
    86/100 stars
      Buy from Supplier

    Image Search Results


    The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts reduced patient survival . ( A ) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor in the patient cohort , organized by ERBB2 status. ( B ) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both WT and KR receptors) in BT-474 human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2 phosphorylation. ( C ) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated ER-positive tumors from the Loi et al. dataset . ( D ) Survival curves as in part C for patients whose tumors expressed the combined T47D metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files and ]. ER, estrogen receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.

    Journal: Breast Cancer Research : BCR

    Article Title: Phosphorylated and sumoylation-deficient progesterone receptors drive proliferative gene signatures during breast cancer progression

    doi: 10.1186/bcr3211

    Figure Lengend Snippet: The SUMO-deficient PR gene expression signature is associated with HER2-positive human breast tumors and predicts reduced patient survival . ( A ) Normalized gene expression levels (for genes in our LD KR > WT gene signature) are presented for each tumor in the patient cohort , organized by ERBB2 status. ( B ) Gene expression levels were measured by RT-qPCR for CHN2 and RGS2 (both upregulated by SUMO-deficient PR, and members of the LD KR > WT gene signature) and the control gene ACOT6 (equally upregulated by both WT and KR receptors) in BT-474 human breast cancer cells. Cells were pre-treated with MEK kinase inhibitor U0126 prior to progestin or antiprogestin co-treatment. Protein levels were evaluated by western blotting for total PR, PR Ser294 phosphorylation, total ERK1/2, and ERK1/2 phosphorylation. ( C ) Kaplan-Meier survival curve for distant metastasis free survival for patients whose tumors expressed the combined T47D metagenes (WT or KR, -/+R5020) relative to patient tumors lacking these metagenes. Patient samples include untreated and tamoxifen-treated ER-positive tumors from the Loi et al. dataset . ( D ) Survival curves as in part C for patients whose tumors expressed the combined T47D metagenes (KR -R5020, or KR +R5020) relative to patient tumors lacking these metagenes. [See also Additional files and ]. ER, estrogen receptor; KR, K388R PR-B mutant; LD, ligand dependent; SUMO, small ubiquitin-like modifier; WT, wild type.

    Article Snippet: BT-474 cells (ATCC, Manassas, VA, USA) were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (Gibco, Grand Island, NY, USA, catalog #11875) supplemented with 10% FBS, 1% penicillin/streptomycin.

    Techniques: Expressing, Quantitative RT-PCR, Western Blot, Mutagenesis

    MCF-7, BT-474, and EFM-192a cells were stimulated with 50ng/mL of either FGF2 or FGF4 supplemented with 5µg/mL of heparin. After 0, 30, and 60 minutes, the cells were harvested and subjected to measurement using the targeted kinome assay. The heatmap shows the quantified activation-determining phosphorylated sites on the kinases (biological triplicates). Only significantly changing values are shown (ANOVA p < 0.05).

    Journal: bioRxiv

    Article Title: Elucidating Fibroblast Growth Factor-induced kinome dynamics using targeted mass spectrometry and dynamic modeling

    doi: 10.1101/2023.01.27.525819

    Figure Lengend Snippet: MCF-7, BT-474, and EFM-192a cells were stimulated with 50ng/mL of either FGF2 or FGF4 supplemented with 5µg/mL of heparin. After 0, 30, and 60 minutes, the cells were harvested and subjected to measurement using the targeted kinome assay. The heatmap shows the quantified activation-determining phosphorylated sites on the kinases (biological triplicates). Only significantly changing values are shown (ANOVA p < 0.05).

    Article Snippet: MCF-7 (ATCC), BT-474 (ATCC), and EFM-192a (DSMZ) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS (Sigma) and 2mM glutamine.

    Techniques: Activation Assay

    FGFR expression levels were quantified using qPCR in MCF-7, BT-474, and EFM-192a cells using FGFR subtype-specific primers (triplicate measurements) ( Supplementary table 5 ). Beta-actin and Glyceraldehyde-3-phosphate dehydrogenase was quantified to enable normalization across cell types. Reported values are the quantitation cycles (Cq) that negatively correlates with the RNA expression levels.

    Journal: bioRxiv

    Article Title: Elucidating Fibroblast Growth Factor-induced kinome dynamics using targeted mass spectrometry and dynamic modeling

    doi: 10.1101/2023.01.27.525819

    Figure Lengend Snippet: FGFR expression levels were quantified using qPCR in MCF-7, BT-474, and EFM-192a cells using FGFR subtype-specific primers (triplicate measurements) ( Supplementary table 5 ). Beta-actin and Glyceraldehyde-3-phosphate dehydrogenase was quantified to enable normalization across cell types. Reported values are the quantitation cycles (Cq) that negatively correlates with the RNA expression levels.

    Article Snippet: MCF-7 (ATCC), BT-474 (ATCC), and EFM-192a (DSMZ) cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS (Sigma) and 2mM glutamine.

    Techniques: Expressing, Quantitation Assay, RNA Expression

    The targeting ability of the NIHA complex. The CLSM images of BT-474 cells incubated with the NIHA complex (up) and the nanobubble-Dil-HPPH complex (down). Bar, 50 μm.

    Journal: International Journal of Nanomedicine

    Article Title: The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer

    doi: 10.2147/IJN.S387409

    Figure Lengend Snippet: The targeting ability of the NIHA complex. The CLSM images of BT-474 cells incubated with the NIHA complex (up) and the nanobubble-Dil-HPPH complex (down). Bar, 50 μm.

    Article Snippet: The BT-474 cell line and the MDA-MB-231 cell line were purchased from the American Type Culture Collection (USA).

    Techniques: Incubation

    ( A ) Cell viability of BT-474 cells detected via CCK-8. ( B ) The apoptotic ratio of BT-474 cells detected via Annexin-V flow cytometry. ** P < 0.01 compared with the NIHA-laser group.

    Journal: International Journal of Nanomedicine

    Article Title: The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer

    doi: 10.2147/IJN.S387409

    Figure Lengend Snippet: ( A ) Cell viability of BT-474 cells detected via CCK-8. ( B ) The apoptotic ratio of BT-474 cells detected via Annexin-V flow cytometry. ** P < 0.01 compared with the NIHA-laser group.

    Article Snippet: The BT-474 cell line and the MDA-MB-231 cell line were purchased from the American Type Culture Collection (USA).

    Techniques: CCK-8 Assay, Flow Cytometry

    CLSM images of BT-474 cells in the NIHA-laser, NIHA, laser, and the control groups. The nuclei of the apoptosis cells were stained by using PI (depicted as red fluorescence). Bar, 30 μm.

    Journal: International Journal of Nanomedicine

    Article Title: The Combined Effect of Nanobubble-IR783-HPPH-Affibody Complex and Laser on HER2-Positive Breast Cancer

    doi: 10.2147/IJN.S387409

    Figure Lengend Snippet: CLSM images of BT-474 cells in the NIHA-laser, NIHA, laser, and the control groups. The nuclei of the apoptosis cells were stained by using PI (depicted as red fluorescence). Bar, 30 μm.

    Article Snippet: The BT-474 cell line and the MDA-MB-231 cell line were purchased from the American Type Culture Collection (USA).

    Techniques: Staining, Fluorescence

    MCF-7 and BT-474 cells were cultured on soft (0.5 kPa) or stiff (9 kPa) supports for 2 weeks before subsequent analysis. a Docetaxel (Doc) induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. The proportions of Annexin V + cells are shown. b Quantitation of apoptotic cells (Annexin V + ) in MCF-7 and BT-474 cells in (a) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. c MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated after 24 h by CCK8 assays ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. d Western blots for cleaved/uncleaved caspase-3 and PARP in docetaxel-treated MCF-7 and BT-474 cells cultured on soft or stiff supports. Representative images from 3 biologically independent experiments are shown. e The percentage of CD44 high CD24 low cells in MCF-7 and BT-474 cells cultured on soft or stiff supports were determined by flow cytometry. f Quantitation of CD44 high CD24 low cells in (e) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. For b-d and f , source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Niche stiffness sustains cancer stemness via TAZ and NANOG phase separation

    doi: 10.1038/s41467-023-35856-y

    Figure Lengend Snippet: MCF-7 and BT-474 cells were cultured on soft (0.5 kPa) or stiff (9 kPa) supports for 2 weeks before subsequent analysis. a Docetaxel (Doc) induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. The proportions of Annexin V + cells are shown. b Quantitation of apoptotic cells (Annexin V + ) in MCF-7 and BT-474 cells in (a) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. c MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated after 24 h by CCK8 assays ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. d Western blots for cleaved/uncleaved caspase-3 and PARP in docetaxel-treated MCF-7 and BT-474 cells cultured on soft or stiff supports. Representative images from 3 biologically independent experiments are shown. e The percentage of CD44 high CD24 low cells in MCF-7 and BT-474 cells cultured on soft or stiff supports were determined by flow cytometry. f Quantitation of CD44 high CD24 low cells in (e) ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided Student’s t test. For b-d and f , source data are provided as a Source Data file.

    Article Snippet: MCF-7 cells (cat#HTB-22) and BT-474 cells (cat#HTB-20) cells were obtained from American Type Culture Collection (ATCC) and cultured according to standard protocols.

    Techniques: Cell Culture, Flow Cytometry, Quantitation Assay, Western Blot

    MCF-7 and BT-474 cells were cultured on soft or stiff supports for 2 weeks before subsequent analysis. In some experiments, cells were pre-transduced with TAZ shRNA (shTAZ-1 or shTAZ-2) or GFP shRNA (shGFP). a The expression of TAZ in MCF-7 and BT-474 cells cultured on soft or stiff supports was determined by western blot ( n = 3 biologically independent experiments). b Representative immunofluorescence staining of TAZ in MCF-7 and BT-474 cells cultured on soft or stiff substrates. The insert represents a magnification from the indicated area (white square). Scale bars, 10 μm. c Proportion of cancer cells exhibiting mainly nuclear TAZ localization (N > C), diffuse distribution of TAZ in nucleus and cytoplasm (N = C), or preferential cytoplasmic TAZ (N < C or undetectable). 20 cells were assessed per group, experiments were independently repeated 4 times. Mean ± SD, **** p < 0.0001 by two-tailed chi-square test. d Docetaxel induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. See Supplementary Fig. for quantification. e MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated by CCK8 assay ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided one-way ANOVA with Tukey test. f Representative images of CD44 high CD24 low cells in MCF-7 and BT-474 cells were detected by flow cytometry. See Supplementary Fig. for quantification. g Western blots of TAZ, SOX2, and OCT4 in MCF-7 and BT-474 cells cultured on soft or stiff supports ( n = 3 biologically independent experiments). For data presented in the same figure panel, the samples were derived from the same experiment and blots were processed in parallel. For a , c , e and g , source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Niche stiffness sustains cancer stemness via TAZ and NANOG phase separation

    doi: 10.1038/s41467-023-35856-y

    Figure Lengend Snippet: MCF-7 and BT-474 cells were cultured on soft or stiff supports for 2 weeks before subsequent analysis. In some experiments, cells were pre-transduced with TAZ shRNA (shTAZ-1 or shTAZ-2) or GFP shRNA (shGFP). a The expression of TAZ in MCF-7 and BT-474 cells cultured on soft or stiff supports was determined by western blot ( n = 3 biologically independent experiments). b Representative immunofluorescence staining of TAZ in MCF-7 and BT-474 cells cultured on soft or stiff substrates. The insert represents a magnification from the indicated area (white square). Scale bars, 10 μm. c Proportion of cancer cells exhibiting mainly nuclear TAZ localization (N > C), diffuse distribution of TAZ in nucleus and cytoplasm (N = C), or preferential cytoplasmic TAZ (N < C or undetectable). 20 cells were assessed per group, experiments were independently repeated 4 times. Mean ± SD, **** p < 0.0001 by two-tailed chi-square test. d Docetaxel induced apoptosis of MCF-7 and BT-474 was assessed by flow cytometry. See Supplementary Fig. for quantification. e MCF-7 and BT-474 cells cultured on soft or stiff supports were treated with docetaxel or cisplatin. Cell viability was evaluated by CCK8 assay ( n = 5 biologically independent experiments). Mean ± SD, **** p < 0.0001 by two-sided one-way ANOVA with Tukey test. f Representative images of CD44 high CD24 low cells in MCF-7 and BT-474 cells were detected by flow cytometry. See Supplementary Fig. for quantification. g Western blots of TAZ, SOX2, and OCT4 in MCF-7 and BT-474 cells cultured on soft or stiff supports ( n = 3 biologically independent experiments). For data presented in the same figure panel, the samples were derived from the same experiment and blots were processed in parallel. For a , c , e and g , source data are provided as a Source Data file.

    Article Snippet: MCF-7 cells (cat#HTB-22) and BT-474 cells (cat#HTB-20) cells were obtained from American Type Culture Collection (ATCC) and cultured according to standard protocols.

    Techniques: Cell Culture, Transduction, shRNA, Expressing, Western Blot, Immunofluorescence, Staining, Two Tailed Test, Flow Cytometry, CCK-8 Assay, Derivative Assay

    a – d TAZ and NANOG were knockout or overexpressed by lentiviral transfection in MCF-7 and BT-474 cells. NANOG, TAZ, SOX2 or/and OCT4 were overexpressed in TAZ or NANOG knockout cells. Transfected cells were cultured on stiff hydrogels for 2 weeks. OE, overexpression. a (Left) Representative flow cytometric plot indicating the percentages of CD44 high CD24 low cells in MCF-7 and BT-474 cells. (Right) Qualification of five biologically independent experiments. **** p < 0.0001; for MCF-7 cells, *** p = 0.0003, ** p = 0.0039, ns=0.9899; for BT-474 cells, *** p = 0.0008, ns=0.9982. b Cell viability of MCF-7 and BT-474 cells treated with various concentrations of docetaxel and cisplatin for 24 h was determined by CCK8 assays ( n = 4 biologically independent experiments). P values compared with sgTAZ + Vector group were shown in the figure. c (Left) Representative flow cytometric plot indicating the percentages of CD44 high CD24 low cells in MCF-7 and BT-474 cells. (Right) Qualification of five independent experiments. **** p < 0.0001; for MCF-7 cells, *** p = 0.0004, ** p = 0.0033, ns=0.9400; for BT-474 cells, *** p = 0.0002, ** p = 0.0013, ns=0.9982. d Cell viability of MCF-7 and BT-474 cells treated with various concentrations of docetaxel and cisplatin for 24 h was determined by CCK8 assays ( n = 4 biologically independent experiments). P values compared with sgNANOG + Vector group were shown in the figure. For panels (a– d) , data are mean ± SD; p values were calculated by two-sided one-way ANOVA with Tukey test. e , f MCF-7 cells were cultured on soft or stiff hydrogels for 2 weeks. Then ChIP was performed using cell lysates with indicated antibodies. e The precipitated DNA using IgG and TAZ antibody, respectively, was quantified by qPCR with primers specific to promoter regions of Sox2 and Pou5f1 . f The precipitated DNA using IgG and NANOG antibody, respectively, was quantified by qPCR with primers specific to promoter regions of Sox2 and Pou5f1 . e , f Fold enrichment was normalized to IgG-ChIP negative control ( n = 4 biologically independent experiments). Numeric values denote mean ± SD; **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. For a–f , source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Niche stiffness sustains cancer stemness via TAZ and NANOG phase separation

    doi: 10.1038/s41467-023-35856-y

    Figure Lengend Snippet: a – d TAZ and NANOG were knockout or overexpressed by lentiviral transfection in MCF-7 and BT-474 cells. NANOG, TAZ, SOX2 or/and OCT4 were overexpressed in TAZ or NANOG knockout cells. Transfected cells were cultured on stiff hydrogels for 2 weeks. OE, overexpression. a (Left) Representative flow cytometric plot indicating the percentages of CD44 high CD24 low cells in MCF-7 and BT-474 cells. (Right) Qualification of five biologically independent experiments. **** p < 0.0001; for MCF-7 cells, *** p = 0.0003, ** p = 0.0039, ns=0.9899; for BT-474 cells, *** p = 0.0008, ns=0.9982. b Cell viability of MCF-7 and BT-474 cells treated with various concentrations of docetaxel and cisplatin for 24 h was determined by CCK8 assays ( n = 4 biologically independent experiments). P values compared with sgTAZ + Vector group were shown in the figure. c (Left) Representative flow cytometric plot indicating the percentages of CD44 high CD24 low cells in MCF-7 and BT-474 cells. (Right) Qualification of five independent experiments. **** p < 0.0001; for MCF-7 cells, *** p = 0.0004, ** p = 0.0033, ns=0.9400; for BT-474 cells, *** p = 0.0002, ** p = 0.0013, ns=0.9982. d Cell viability of MCF-7 and BT-474 cells treated with various concentrations of docetaxel and cisplatin for 24 h was determined by CCK8 assays ( n = 4 biologically independent experiments). P values compared with sgNANOG + Vector group were shown in the figure. For panels (a– d) , data are mean ± SD; p values were calculated by two-sided one-way ANOVA with Tukey test. e , f MCF-7 cells were cultured on soft or stiff hydrogels for 2 weeks. Then ChIP was performed using cell lysates with indicated antibodies. e The precipitated DNA using IgG and TAZ antibody, respectively, was quantified by qPCR with primers specific to promoter regions of Sox2 and Pou5f1 . f The precipitated DNA using IgG and NANOG antibody, respectively, was quantified by qPCR with primers specific to promoter regions of Sox2 and Pou5f1 . e , f Fold enrichment was normalized to IgG-ChIP negative control ( n = 4 biologically independent experiments). Numeric values denote mean ± SD; **** p < 0.0001 by two-sided two-way ANOVA with Tukey test. For a–f , source data are provided as a Source Data file.

    Article Snippet: MCF-7 cells (cat#HTB-22) and BT-474 cells (cat#HTB-20) cells were obtained from American Type Culture Collection (ATCC) and cultured according to standard protocols.

    Techniques: Knock-Out, Transfection, Cell Culture, Over Expression, Plasmid Preparation, Negative Control

    Hierarchical clustering of RNA expression profiles. Panel A clustering analysis of expression profiles of 8 MCF-7 sublines along with those of 19 breast cancer cell lines. Expression profiling was done using home made Nylon arrays comprising 721 cDNAs corresponding to identified genes localized on either chromosome 1q or 17q. Panel B clustering analysis of profiles of 7 MCF-7 sublines and the BT-474 breast cancer cell line. Nylon arrays comprised 1034 genes selected on the basis of their involvement in cancer. Clustering analysis wass done on raw quantification results, which were just subjected to a scaling step but not to ratio calculation. Parameters used in the analysis were Hierarchically Cluster Axes for Genesand Array: clusterand similarity metric correlation centered with average linkage clustering. The dendogram on top of the diagram represents cell lines ordered according to their degree of similarity. Complete datasets can be found at

    Journal: BMC Cancer

    Article Title: Genetic variability in MCF-7 sublines: evidence of rapid genomic and RNA expression profile modifications

    doi: 10.1186/1471-2407-3-13

    Figure Lengend Snippet: Hierarchical clustering of RNA expression profiles. Panel A clustering analysis of expression profiles of 8 MCF-7 sublines along with those of 19 breast cancer cell lines. Expression profiling was done using home made Nylon arrays comprising 721 cDNAs corresponding to identified genes localized on either chromosome 1q or 17q. Panel B clustering analysis of profiles of 7 MCF-7 sublines and the BT-474 breast cancer cell line. Nylon arrays comprised 1034 genes selected on the basis of their involvement in cancer. Clustering analysis wass done on raw quantification results, which were just subjected to a scaling step but not to ratio calculation. Parameters used in the analysis were Hierarchically Cluster Axes for Genesand Array: clusterand similarity metric correlation centered with average linkage clustering. The dendogram on top of the diagram represents cell lines ordered according to their degree of similarity. Complete datasets can be found at

    Article Snippet: Seven MCF-7 variants (MCF-7-MVLN, MCF-7-ATCC, MCF-7-MF, MCF-7-MG, MCF-7-R, MCF-7-R-F3 and MCF-7-R-D4) were analyzed together with BT-474 breast cancer cells.

    Techniques: RNA Expression, Expressing